TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Profound Medical ( (TSE:PRN) ) has issued an announcement.
Profound Medical reported a significant 87% increase in revenue year-over-year, reaching a record $5.3 million in the third quarter of 2025. The company also saw a notable increase in gross margin to 74.3%, driven by the growing adoption of its TULSA-PRO system. Profound is expanding its market presence with strategic distribution agreements in Canada, Saudi Arabia, Australia, and New Zealand, and has launched a new TULSA-PROgram in partnership with Texas Prostate and Dallas Medical Center. These developments are expected to accelerate the adoption of its prostate treatment technologies and enhance its positioning in the global medical device industry.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on TSE:PRN Stock
According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.
Profound Medical’s stock score reflects the company’s strong revenue growth and strategic potential, balanced by operational inefficiencies and financial challenges. Technical indicators suggest caution due to bearish trends, while valuation remains a concern with negative earnings. Positive earnings call sentiment and future growth prospects are encouraging, yet immediate operational improvements are necessary for sustained success.
To see Spark’s full report on TSE:PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company that specializes in developing and marketing AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company’s primary focus is on the TULSA-PRO system, which is used for treating prostate diseases, including prostate cancer and benign prostatic hyperplasia (BPH).
Average Trading Volume: 19,874
Technical Sentiment Signal: Hold
Current Market Cap: C$272M
For a thorough assessment of PRN stock, go to TipRanks’ Stock Analysis page.